Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
83.60
-0.21 (-0.25%)
Apr 29, 2026, 9:34 AM EDT - Market open

Nektar Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
2,8218601721084252,493
Upgrade
Market Cap Growth
2352.91%401.35%59.16%-74.63%-82.96%-18.24%
Upgrade
Enterprise Value
2,731757129-201791,866
Upgrade
Last Close Price
83.8142.2813.958.4733.90202.65
Upgrade
PS Ratio
51.2015.571.741.204.6124.47
Upgrade
PB Ratio
19.019.572.820.821.163.67
Upgrade
P/TBV Ratio
31.489.572.820.821.464.14
Upgrade
EV/Sales Ratio
49.4513.701.31-1.9418.31
Upgrade
Debt / Equity Ratio
1.661.663.201.760.780.50
Upgrade
Net Debt / Equity Ratio
-1.08-1.08-1.23-0.76-0.59-0.68
Upgrade
Net Debt / EBITDA Ratio
0.750.750.600.780.961.07
Upgrade
Net Debt / FCF Ratio
0.460.460.420.510.701.08
Upgrade
Asset Turnover
0.190.190.280.160.100.08
Upgrade
Inventory Turnover
---1.911.241.60
Upgrade
Quick Ratio
4.624.624.185.977.538.90
Upgrade
Current Ratio
4.974.974.266.458.019.34
Upgrade
Return on Equity (ROE)
-217.94%-217.94%-124.10%-110.95%-70.39%-59.64%
Upgrade
Return on Assets (ROA)
-27.98%-27.98%-23.14%-15.25%-16.43%-21.00%
Upgrade
Return on Invested Capital (ROIC)
---450.92%-131.09%-111.04%-137.22%
Upgrade
Return on Capital Employed (ROCE)
-57.60%-57.60%-53.60%-39.00%-37.40%-43.20%
Upgrade
Earnings Yield
-5.80%-19.08%-69.35%-256.12%-86.68%-21.01%
Upgrade
FCF Yield
-7.40%-24.34%-103.28%-179.50%-72.91%-17.15%
Upgrade
Buyback Yield / Dilution
-23.05%-23.05%-8.24%-1.53%-2.10%-2.64%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.